Oruka Therapeutics, Inc., a biotechnology company specializing in novel biologics for chronic skin diseases, has announced the commencement of its first clinical trial for ORKA-002. This trial involves dosing healthy volunteers with ORKA-002, a half-life extended monoclonal antibody targeting IL-17A/F, which is administered subcutaneously. The Phase 1 trial is designed as a double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 across three subcutaneous dose cohorts in approximately 24 participants. Interim data from this study is expected by the end of 2025. Oruka aims to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026, with a focus on assessing multiple dose levels and regimens.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.